var data={"title":"Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5950?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">see &quot;Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information&quot;</a> and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154885\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bactrim;</li>\n      <li>Bactrim DS;</li>\n      <li>Sulfatrim Pediatric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154886\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Sulfatrim;</li>\n      <li>Apo-Sulfatrim DS;</li>\n      <li>Apo-Sulfatrim Pediatric;</li>\n      <li>Protrin DF;</li>\n      <li>Septra Injection;</li>\n      <li>Teva-Trimel;</li>\n      <li>Teva-Trimel DS;</li>\n      <li>Trisulfa;</li>\n      <li>Trisulfa DS;</li>\n      <li>Trisulfa S</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046614\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Sulfonamide Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046607\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">see &quot;Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage recommendations are based on the trimethoprim (TMP) component:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Infants &ge;2 months, Children, and Adolescents: Oral, IV: 6 to 12 mg TMP/kg/day in divided doses every 12 hours; maximum single dose: 160 mg TMP/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Limited data available: Infants, Children, and Adolescents: Oral: 5 to 10 mg TMP/kg/dose once daily; maximum dose: 80 mg TMP/dose (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Cyclosporiasis</i>:</b> Limited data available: Infants &ge;2 months, Children, and Adolescents: Oral: 8 to 10 mg TMP/kg/day in divided doses twice daily for 7 to 10 days; maximum single dose: 160 mg TMP (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> Infants &ge;2 months, Children, and Adolescents: IV: 10 to 20 mg TMP/kg/day divided every 6 to 12 hours for 7 to 21 days; duration dependent on the pathogen and clinical course (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>MRSA, community-acquired mild to moderate skin/soft tissue infection:</b> Infants &ge;2 months, Children, and Adolescents: Oral: 8 to 12 mg TMP/kg/day in divided doses every 12 hours (Liu 2011); alternatively, use of 20 mg TMP/kg/day in divided doses every 6 hours has been reported (Long 2012). If using empirically, consider addition of group A streptococcal coverage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Infants &ge;2 months, Children, and Adolescents: Oral: 6 to 10 mg TMP/kg/day in divided doses every 12 hours for 10 days. <b>Note:</b> Due to resistance of <i>S. pneumoniae</i>, should not be used in patients that fail first-line amoxicillin therapy (AAP [Lieberthal 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis jirovecii</i> pneumonia (PCP) (HIV-exposed/-positive):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants (at least 4 weeks of age) and Children: Oral: 5 to 10 mg TMP/kg/day or 150 mg TMP/<b>m<sup>2</sup></b>/day; dose may be given as a single daily dose or in divided doses every 12 hours given 2 to 3 days per week on consecutive days or alternating days; maximum daily dose: TMP 320 mg/<b>day</b> (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 80 to 160 mg TMP daily or alternatively, 160 mg TMP 3 times weekly (HHS [OI adult 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &gt;2 months and Children: Initial: IV: 15 to 20 mg TMP/kg/day in divided doses every 6 hours for 21 days; as acute pneumonitis subsides in patients with mild to moderate disease and no malabsorption issues nor diarrhea, may transition to oral therapy of same daily dose (15 to 20 mg/kg/day TMP) administered in divided doses 3 or 4 times daily (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents (HHS [OI adult 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild to moderate: Oral: 15 to 20 mg TMP/kg/day in 3 divided doses for 21 days <b>or</b> alternatively, 320 mg TMP 3 times daily for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe: Initial: IV: 15 to 20 mg TMP/kg/day in 3 to 4 divided doses for 21 days; may switch to oral after clinical improvement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Q-Fever (</b>\n      <i>\n        <b>Coxiella burnetii</b></i>\n      <b>); mild infection (doxycycline therapeutic failure):</b> Limited data available, dose should be based on severity of illness: Children &lt;8 years: Oral: Usual dose range: 8 to 10 mg TMP/kg/day in divided doses twice daily for 14 days; a wider dose range of 4 to 20 mg TMP/kg/day divided twice daily has been suggested to address varying degrees of severity; however, reported pediatric efficacy experience (eg, case series) are lacking; monitor patients receiving doses at the high and low end of the range closely for efficacy and possible adverse effects (Bradley 2017; CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Shigellosis:</b> Infants &ge;2 months, Children, and Adolescents: <b>Note:</b> Due to reported widespread resistance empiric therapy with sulfamethoxazole and trimethoprim is not recommended (CDC-NARMS 2010; WHO 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: 8 mg TMP/kg/day in divided doses every 12 hours for 5 days; maximum single dose: 160 mg TMP</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: IDSA recommendations for infectious diarrhea: 10 mg TMP/kg/day in divided doses every 12 hours for 3 days (for immunocompetent patients) or 7 to 10 days (for immunocompromised patients); maximum single dose: 160 mg TMP (Guerrant 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 8 to 10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Toxoplasmosis (HIV-exposed/infected):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis, primary:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;2 months and Children: Oral: 150 mg TMP/<b>m<sup>2</sup></b>/day; dose may be administered as a single daily dose (preferred) or in divided doses every 12 hours; alternatively, may also be given 3 times weekly for 3 consecutive or alternating days (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 160 mg TMP daily (preferred) <b>or</b> 160 mg TMP 3 times weekly <b>or</b> 80 mg TMP daily (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment, encephalitis:</i> Adolescents: Oral, IV: 10 mg/kg/day TMP in two divided doses for at least 6 weeks; longer duration may be required in some patients; following treatment all patients should receive chronic maintenance therapy daily (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary prophylaxis (chronic suppressive therapy, alternative regimen):</i> <b>Note: </b>Only use when pyrimethamine is unavailable or not tolerated:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Oral: 150 mg TMP<b>/m<sup>2</sup></b>/day once daily (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: <i>Maintenance therapy; postencephalitis treatment:</i> Oral: 160 mg TMP once or twice daily: May discontinue when asymptomatic and CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months in response to ART. <b>Note:</b> Once-daily dosing may be associated with an increased risk of relapse; if used, a gradual transition (eg, follow acute treatment with 4 to 6 weeks of 160 mg TMP twice daily before lowering to once-daily dosing) may be beneficial (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children 2 to 24 months: 6 to 12 mg TMP/kg/day in divided doses every 12 hours for 7 to 14 days (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;24 months and Adolescents: 8 mg TMP/kg/day in divided doses every 12 hours for 3 days; longer duration may be required in some patients; maximum single dose: 160 mg TMP</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Infants &ge;2 months, Children, and Adolescents: 8 to 10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 14 days with serious infections</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i> Infants &ge;2 months, Children, and Adolescents: Oral: 2 mg TMP/kg/dose once daily (Mattoo 2007; <i>Red Book</i> [AAP 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dosage recommendations are based on the trimethoprim component. Double-strength tablets are equivalent to sulfamethoxazole 800 mg and trimethoprim 160 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 1 to 2 double strength tablets (sulfamethoxazole 800 mg; trimethoprim 160 mg) every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 8 to 20 mg TMP/kg/day divided every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Infants &ge;2 months, Children, Adolescents, and Adults: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 to 30 mL/minute: Administer 50% of recommended dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Use is not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (Veltri 2004): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/<b>dose</b> every 12 hours. IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute/1.73 m<sup>2</sup>: 3 to 5 mg TMP/kg/<b>dose</b> every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 3 to 5 mg TMP/kg/<b>dose</b> every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: 3 to 5 mg TMP/kg/<b>dose</b> every 24 hours; administer 2.5 mg TMP/kg/<b>dose</b> after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CRRT (CAVH/CVVH/CAVHD/CVVHD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Combined dialysis flow + ultrafiltration rate &lt;1,500 mL/m<sup>2</sup>/hour: 3 to 5 mg TMP/kg/<b>dose</b> every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Combined dialysis flow + ultrafiltration rate &ge; 1,500 mL/m<sup>2</sup>/hour: 4 to 5 mg TMP/kg/<b>dose</b> every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: 2.5 to 10 mg/kg TMP every 24 hours <b>or</b> 5 to 20 mg/kg TMP 3 times weekly after IHD. <b>Note:</b> Dosing is highly dependent upon indication for use (eg, treatment of cystitis versus treatment of PCP pneumonia) (Heinz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVH/CVVHD/CVVHDF: 2.5 to 7.5 mg/kg of TMP every 12 hours. <b>Note:</b> Dosing regimen dependent on clinical indication. Critically-ill patients with <i>P. jirovecii</i> pneumonia receiving CVVHDF may require up to 10 mg/kg every 12 hours (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pneumocystis jirovecii</i> pneumonia (PCP):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children (Veltri 2004): Treatment: <b>Note:</b> Renally adjusted dose recommendations are based on doses of 5 mg/kg/<b>dose</b> every 6 hours. IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 50 mL/minute/1.73 m<sup>2</sup>: 5 mg TMP/kg/<b>dose</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 5 mg TMP/kg/<b>dose</b> every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: 5 mg/kg/dose every 12 hours; administer 2.5 mg TMP/kg/<b>dose</b> after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous renal replacement therapy (CRRT): CAVH/CVVH/CAVHD/CVVHD: 5 mg TMP/kg<b>/dose</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents (HHS [OI adult 2016]): IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 30 mL/minute: 5 mg TMP/kg/<b>dose</b> IV every 12 hours <b>or</b> 320 mg TMP orally every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute: 5 mg TMP/kg/<b>dose</b> IV every 24 hours <b>or</b> 160 mg TMP orally every 12 hours <b>or</b> 320 mg TMP orally every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: 5 mg TMP/kg/<b>dose</b> IV <b>or</b> 320 mg TMP orally; administer dose after dialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis (Masur 2002): Adolescents and Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 15 to 30 mL/minute: 40 mg or 80 mg TMP daily <b>or</b> 80 mg TMP 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;15 mL/minute: 40 mg or 80 mg TMP daily <b>or</b> 80 mg TMP 3 times weekly. While the guidelines do acknowledge the alternative of giving 80 mg TMP daily, this may be inadvisable in the uremic/ESRD patient.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: 40 mg or 80 mg TMP after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; use is contraindicated in cases of marked hepatic damage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154857\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Sulfamethoxazole 80 mg and trimethoprim 16 mg per mL (5 mL, 10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sulfatrim Pediatric: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (473 mL) [contains alcohol, usp, fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow), methylparaben, polysorbate 80, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (20 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactrim: Sulfamethoxazole 400 mg and trimethoprim 80 mg [scored; contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactrim DS: Sulfamethoxazole 800 mg and trimethoprim 160 mg [scored; contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Sulfamethoxazole 400 mg and trimethoprim 80 mg, Sulfamethoxazole 800 mg and trimethoprim 160 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154842\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45703744\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">see &quot;Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">The 5:1 ratio (SMX:TMP) remains constant in all dosage forms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046618\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to meals. Shake suspension well before use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Do not administer IM</b>. IV infusion: Inspect solution for evidence of cloudiness or precipitation prior to administration; infuse diluted solution over 60 to 90 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154877\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Injection: Store at room temperature; do not refrigerate. Less soluble in more alkaline pH. Protect from light. Solution must be diluted prior to administration. Following dilution, store at room temperature; do not refrigerate.  Manufacturer recommended dilutions and stability of parenteral admixture at room temperature (25&deg;C):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">5 mL/125 mL D<sub>5</sub>W; stable for 6 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mL/100 mL D<sub>5</sub>W; stable for 4 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mL/75 mL D<sub>5</sub>W; stable for 2 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Studies have also confirmed limited stability in NS; detailed references should be consulted. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, tablet: Store at controlled room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046617\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of urinary tract infections caused by susceptible <i>E. coli</i>, <i>Klebsiella</i> and <i>Enterobacter</i> sp., <i>M. morganii</i>, <i>P. mirabilis</i> and <i>P. vulgaris</i> (FDA approved in ages &ge;2 months and adults); single course treatment of acute otitis media due to <i>H. influenzae</i> or <i>S. pneumoniae</i> (FDA approved in ages &ge;2 months and adults); prophylaxis and treatment of <i>Pneumocystis jirovecii</i> pneumonitis (PCP) [FDA approved in pediatric patients (age not specified) and adults]; treatment of enteritis caused by <i>Shigella flexneri</i> or <i>Shigella sonnei</i> (FDA approved in ages &ge;2 months and adults); acute exacerbations of chronic bronchitis due to susceptible strains of <i>H. influenzae</i> or <i>S. pneumoniae</i> (FDA approved in adults); traveler's diarrhea due to enterotoxigenic <i>E. coli</i> (FDA approved in adults). Has also been used for the treatment of typhoid fever, Q fever, <i>Nocardia asteroids</i>, MRSA, and <i>Stenotrophomonas maltophilia</i> infections and for the treatment of exit-site or tunnel infections in patients with peritoneal dialysis catheters</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of <i>Pneumocystis jirovecii</i> pneumonitis (PCP), <i>Shigella</i>, and severe or complicated urinary tract infections due to<i> E. coli</i>, <i>Klebsiella</i>, and <i>Enterobacter</i> spp, <i>M. morganii</i>, <i>P. mirabilis</i>, and <i>P. vulgaris</i> (FDA approved in ages &ge;2 months and adults); has also been used in treatment of severe or complicated infections caused by susceptible bacteria when oral therapy is not feasible, including typhoid fever and <i>Nocardia asteroides</i> infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154917\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactrim may be confused with bacitracin, Bactine, Bactroban</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Co-trimoxazole may be confused with clotrimazole </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Septra may be confused with Ceptaz, Sectral</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Septra DS may be confused with Semprex-D</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154912\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Allergic myocarditis, periarteritis nodosa (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Apathy, aseptic meningitis, ataxia, chills, depression, fatigue, hallucination, headache, insomnia, nervousness, peripheral neuritis, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme (rare), exfoliative dermatitis (rare), pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperkalemia (generally at high dosages), hypoglycemia (rare), hyponatremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, glottis edema, kernicterus (in neonates), nausea, pancreatitis, pseudomembranous colitis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Crystalluria, diuresis (rare), nephrotoxicity (in association with cyclosporine), toxic nephrosis (with anuria and oliguria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anaphylactoid purpura (IgA vasculitis; rare), aplastic anemia, eosinophilia, hemolysis (with G6PD deficiency), hemolytic anemia, hypoprothrombinemia, leukopenia, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatotoxicity (including hepatitis, cholestasis, and hepatic necrosis), hyperbilirubinemia, increased transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, rhabdomyolysis (mainly in AIDS patients), systemic lupus erythematosus (rare), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctival injection, injected sclera</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, interstitial nephritis, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Dysgeusia (Syed 2016), immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura), prolonged Q-T interval on ECG, thrombotic thrombocytopenic purpura</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154864\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any sulfa drug, trimethoprim, or any component of the formulation; history of drug induced-immune thrombocytopenia with use of sulfonamides or trimethoprim; megaloblastic anemia due to folate deficiency; infants &lt;2 months (manufacturer's labeling), infants &lt;4 weeks (CDC 2009); marked hepatic damage or severe renal disease (if patient not monitored); concomitant administration with dofetilide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the FDA approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &ldquo;Warnings/Precautions&rdquo; for more detail.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Blood dyscrasias; pregnancy; breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154846\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia, and other blood dyscrasias have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred; discontinue use at first sign of rash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: May cause hyperkalemia; potential risk factors for trimethoprim-induced hyperkalemia include high dosage (20 mg/kg/day of trimethoprim), renal impairment, older age, hypoaldosteronism, and concomitant use of medications causing or exacerbating hyperkalemia (Perazella 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: May cause hypoglycemia, particularly in malnourished, or patients with renal or hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyponatremia: Severe and symptomatic hyponatremia may occur, particularly in patients treated for <i>Pneumocystis jirovecii</i> pneumonia (PCP).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Immune mediated thrombocytopenia may occur. Severe cases which may be life-threatening or fatal have been reported. Thrombocytopenia usually resolves within 1 week following discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma/allergies: Use with caution in patients with allergies or asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. Maintain adequate hydration to prevent crystalluria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leucovorin: Avoid concomitant use when treating <i>Pneumocystis jirovecii</i> pneumonia (PCP) in HIV patients; may increase risk of treatment failure and death.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS patients: Incidence of adverse effects appears to be increased in patients with AIDS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; greater risk for more severe adverse reactions, including hyperkalemia associated with trimethoprim use. Elderly patients are at an increased risk for severe and potentially life-threatening hyperkalemia when trimethoprim is used concomitantly with medications known to cause or exacerbate hyperkalemia, such as spironolactone, ACE inhibitors, or ARBs (Antoniou 2010; Antoniou 2011; Antoniou, 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur (dose-related).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients with potential for folate deficiency: Use with caution in patients with potential folate deficiency (malnourished, chronic anticonvulsant therapy, or elderly).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Use with caution in patients with porphyria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnant women: Use during pregnancy may be associated with embryo-fetal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Slow acetylators: May be more prone to adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfite sensitivity: Injection may contain sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible persons. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic persons.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: When used for uncomplicated urinary tract infections, this combination should not be used if a single agent is effective. Additionally, sulfonamides should not be used to treat group A beta-hemolytic streptococcal infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25956058\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfa antibiotics have been shown to displace bilirubin from protein binding sites which may potentially lead to hyperbilirubinemia and kernicterus in neonates and young infants; do not use in neonates; avoid use in infants &lt;2 months unless other options are not available (eg, <i>Pneumocystis</i>). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154902\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154851\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12816&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amodiaquine: Trimethoprim may enhance the neutropenic effect of Amodiaquine. Trimethoprim may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Trimethoprim may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Sulfamethoxazole may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May diminish the therapeutic effect of Sulfonamide Antibiotics. Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Sulfonamide Antibiotics may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Trimethoprim may increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Trimethoprim may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Trimethoprim may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamiVUDine: Trimethoprim may increase the serum concentration of LamiVUDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. Memantine may increase the serum concentration of Trimethoprim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: Sulfamethoxazole may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim.  Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Sulfamethoxazole may increase the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Sulfamethoxazole may increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of sulfamethoxazole. Monitor for decreased pralatrexate levels with discontinuation of sulfamethoxazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procaine: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of Trimethoprim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Sulfonamide Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazolidinediones: Trimethoprim may decrease the metabolism of Thiazolidinediones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Sulfonamide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154854\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154867\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Sulfamethoxazole and trimethoprim cross the placenta and distribute to amniotic fluid (Ylikorkala, 1973). An increased risk of congenital malformations (neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, club foot) following maternal use of sulfamethoxazole and trimethoprim during pregnancy has been observed in some studies. Folic acid supplementation may decrease this risk (Crider 2009; Czeizel 2001; Hernandez-Diaz 2000; Hernandez-Diaz 2001; Matok 2009). Due to theoretical concerns that sulfonamides pass the placenta and may cause kernicterus in the newborn, neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery (DHHS 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The pharmacokinetics of sulfamethoxazole and trimethoprim are similar to nonpregnant values in early pregnancy (Ylikorkala 1973). Sulfamethoxazole and trimethoprim are recommended for the prophylaxis or treatment of <i>Pneumocystis jirovecii</i> pneumonia (PCP), prophylaxis of <i>Toxoplasmic gondii</i> encephalitis (TE), and for the acute and chronic treatment of Q fever in pregnancy (CDC 2013; DHHS 2013). Sulfonamides may also be used to treat other infections in pregnant women when clinically appropriate; use during the first trimester should be limited to situations where no alternative therapies are available (ACOG 2011). Because safer options are available for the treatment of urinary tract infections in pregnant women, use of TMP-containing products in the first trimester and sulfonamide-containing products &gt;32 weeks gestation should be avoided (Lee 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046613\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, renal function test, liver function test, urinalysis; observe for change in bowel frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154845\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sulfamethoxazole interferes with bacterial folic acid synthesis and growth via inhibition of dihydrofolic acid formation from para-aminobenzoic acid; trimethoprim inhibits dihydrofolic acid reduction to tetrahydrofolate resulting in sequential inhibition of enzymes of the folic acid pathway</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154863\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid; almost completely (90% to 100%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Both SMX and TMP distribute to middle ear fluid, sputum, vaginal fluid; TMP also distributes into bronchial secretions</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: TMP:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Newborns: ~2.7 L/kg (range: 1.3 to 4.1 hours) (Springer 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants: 1.5 L/kg (Hoppu 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 10 years: 0.86 to 1 L/kg (Hoppu 1987) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: ~1.3 L/kg (Hoppu 1987) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: SMX:  ~70%, TMP: ~44% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, both to multiple metabolites; SMX to hydroxy  (via CYP2C9) and acetyl derivatives, and also conjugated with glucuronide; TMP to oxide and hydroxy derivatives; the free forms of both SMX and TMP are therapeutically active </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TMP: Prolonged in renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Newborns: ~19 hours; range: 11 to 27 hours (Springer 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 months to 1 year: ~4.6 hours; range: 3 to 6 hours (Hoppu 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 10 years: 3.7 to 5.5 hours (Hoppu 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents &gt;10 years: 8.19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 6 to 11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SMX: 9 to 12 hours, prolonged in renal failure </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Both are excreted in urine as metabolites and unchanged drug </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154866\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sulfamethoxazole-Trimethoprim Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-80 mg/5 mL (5 mL): $7.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Sulfamethoxazole-Trimethoprim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-40 mg/5 mL (473 mL): $215.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Sulfatrim Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-40 mg/5 mL (473 mL): $112.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bactrim DS Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800-160 mg (100): $311.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bactrim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-80 mg (100): $172.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sulfamethoxazole-Trimethoprim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-80 mg (100): $66.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800-160 mg (100): $115.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154870\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abacin (IT);</li>\n      <li>Acuco (ZA);</li>\n      <li>Alcorim-F (IN);</li>\n      <li>Anitrim (MX);</li>\n      <li>Avlotrin (BD);</li>\n      <li>Bacdan (TW);</li>\n      <li>Bacin (MY, SG, TH);</li>\n      <li>Bactelan (MX);</li>\n      <li>Bacteric (MX);</li>\n      <li>Bacterol (CL);</li>\n      <li>Bacterol Forte (CL);</li>\n      <li>Bacticel (AR);</li>\n      <li>Bactiver (MX);</li>\n      <li>Bactoprim (TH);</li>\n      <li>Bactramin (JP);</li>\n      <li>Bactrim (AE, AR, AT, AU, BB, BE, BH, BR, CH, CY, CZ, DE, DK, EC, EE, EG, FR, IN, IQ, IR, IT, JO, KW, LB, LV, LY, MT, MX, NO, OM, PK, PL, PT, QA, SA, SE, SK, SY, TH, TR, VN, YE);</li>\n      <li>Bactrim DS (AU, BB);</li>\n      <li>Bactrim F (CO);</li>\n      <li>Bactrim Forte (AT, FI, FR, LU, PH, PT, SE);</li>\n      <li>Bactrimel (GR, VE);</li>\n      <li>Bactropin (MX);</li>\n      <li>Baktrym (UA);</li>\n      <li>Biseptol (BG, LV, UA);</li>\n      <li>Brogamax (MX);</li>\n      <li>Co-Try (BD);</li>\n      <li>Colizole (IN);</li>\n      <li>Colizole DS (IN);</li>\n      <li>Cotrim (BF, BJ, CI, ET, GH, GM, GN, KE, KR, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Cotrim DS (MY);</li>\n      <li>Cotrimel (HK);</li>\n      <li>Cotrix (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Cotrizol (TW);</li>\n      <li>Deprim (MT);</li>\n      <li>Dhatrim (MY);</li>\n      <li>Dibaprim (MX);</li>\n      <li>Diseptyl (IL);</li>\n      <li>Duocide (TW);</li>\n      <li>Duratrimet (DE);</li>\n      <li>Ectaprim (MX);</li>\n      <li>Epitrim (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, RO, SA, SY, YE);</li>\n      <li>Escoprim (CH);</li>\n      <li>Espectrin (BR);</li>\n      <li>Eusaprim (AT, BE, FI, IS, IT, NO, SE);</li>\n      <li>Farcotrim (QA);</li>\n      <li>Fectrim (GB);</li>\n      <li>Gantaprim (IT);</li>\n      <li>Gantrim (IT);</li>\n      <li>Ikaprim (ID);</li>\n      <li>Infectrim (PE);</li>\n      <li>Introcin (CL);</li>\n      <li>Isotrim (IT);</li>\n      <li>Kepinol (DE);</li>\n      <li>Lagatrim (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Lagatrim Forte (BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LB, LR, MA, ML, MR, MU, MW, NE, NG, NL, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Lidaprim (AE, SA);</li>\n      <li>Lidaprim Forte (AE, AT, SA);</li>\n      <li>Mano-Trim (TH);</li>\n      <li>Mano-Trim Forte (TH);</li>\n      <li>Medixin (IT);</li>\n      <li>Metoxiprim (MX);</li>\n      <li>Metrim (TH);</li>\n      <li>Microtrim (DE);</li>\n      <li>Morbifurb (CN);</li>\n      <li>Mortin (VN);</li>\n      <li>Nopil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Octex (MX);</li>\n      <li>Omsat (BF, BJ, CI, DE, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Oriprim (RU);</li>\n      <li>Oriprim DS (KE, TZ, UG, ZW);</li>\n      <li>Oxaprim (IT);</li>\n      <li>Politrim (BD);</li>\n      <li>Primzole (SG);</li>\n      <li>Purbal (ZA);</li>\n      <li>Resprim (AU);</li>\n      <li>Resprim Forte (AU);</li>\n      <li>Sanprima (ID);</li>\n      <li>Sanprima Forte (ID);</li>\n      <li>Septran (IN, PK, PY);</li>\n      <li>Septran Forte (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Septrin (AE, AU, BF, BH, BJ, CI, CY, EG, ES, ET, GB, GH, GM, GN, ID, IE, IQ, IR, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, OM, PE, PH, QA, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, VN, YE, ZM, ZW);</li>\n      <li>Septrin DS (HK);</li>\n      <li>Septrin Forte (AU);</li>\n      <li>Servitrim (MX);</li>\n      <li>Sevatrim (KR);</li>\n      <li>Sigaprim (DE);</li>\n      <li>Sinersul (HR);</li>\n      <li>Soltrim (MX);</li>\n      <li>Suftrex (EC);</li>\n      <li>Sulfacet (DE);</li>\n      <li>Sulfoid Trimetho (MX);</li>\n      <li>Sulfotrimin (DE);</li>\n      <li>Sulotrim (HR);</li>\n      <li>Suntrim (TH);</li>\n      <li>Suntrim Forte (TH);</li>\n      <li>Suprim (PE);</li>\n      <li>Suprin (IT);</li>\n      <li>Tagremin (RO);</li>\n      <li>Timexole (MX);</li>\n      <li>TMS (DE);</li>\n      <li>Trim (IT, ZA);</li>\n      <li>Trimaxazole (SG);</li>\n      <li>Trimetoger (MX);</li>\n      <li>Trimexan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Trimexazol (MX);</li>\n      <li>Trimexazole (TH);</li>\n      <li>Trimezol (BG);</li>\n      <li>Trimoprim (HK);</li>\n      <li>Trimox (TW);</li>\n      <li>Trimoxis (PH);</li>\n      <li>Triomax (JO);</li>\n      <li>Trisolvat (CO);</li>\n      <li>Trisul (BD, NZ);</li>\n      <li>Trizole (PH);</li>\n      <li>Tryseptol (UA);</li>\n      <li>Xepaprim (ID);</li>\n      <li>Xepaprim Forte (ID);</li>\n      <li>Zoltrim (EC);</li>\n      <li>Zultrop (ID);</li>\n      <li>Zultrop Forte (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Subcommittee on Urinary Tract Infection, &quot;Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months,&quot; <i>Pediatrics</i>, 2011, 128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 494: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1484-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/21606771/pubmed\" target=\"_blank\" id=\"21606771\">21606771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007, 154.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashkenazi S, Amir J, Waisman Y, et al, &quot;A Randomized, Double-Blind Study Comparing Cefixime and Trimethoprim-Sulfamethoxazole in the Treatment of Childhood Shigellosis,&quot; <i>J Pediatr</i>, 1993, 123(5):817-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/8229498/pubmed\" target=\"_blank\" id=\"8229498\">8229498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bactrim injection (sulfamethoxazole and trimethoprim) [prescribing information]. Cranberry, NJ: Sun Pharmaceutical Industries, Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Diagnosis and Management of Q Fever - United States, 2013: Recommendations From CDC and the Q Fever Working Group,&quot; <i>MMWR Recomm Rep</i>, 2013, 62(RR-03):1-30. Errata: <i>MMWR</i>. 2013:62(35); 730. Available at <a href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6235a8.htm\" target=\"_blank\">https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6235a8.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; MMWR Recomm Rep, 2009, 58(RR-11):1-166. Available at http://www.antimicrobe.org/h04c.files/history/CDC-HIV%20ExposeInfectChildren-2009.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2010,&quot; Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crider KS, Cleves MA, Reefhuis J, et al, &quot;Antibacterial Medication Use During Pregnancy and Risk of Birth Defects: National Birth Defects Prevention Study,&quot; <i>Arch Pediatr Adolesc Med</i>, 2009, 163(11):978-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19884587/pubmed\" target=\"_blank\" id=\"19884587\">19884587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czeizel AE, Rockenbauer M, S&oslash;rensen HT, et al, &quot;The Teratogenic Risk of Trimethoprim-Sulfonamides: A Population Based Case-Control Study,&quot; <i>Reprod Toxicol</i>, 2001, 15(6):637-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11738517/pubmed\" target=\"_blank\" id=\"11738517\">11738517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Della-Giustina K and Chow G, &quot;Medications in Pregnancy and Lactation,&quot; <i>Emerg Med Clin North Am</i>, 2003, 21(3):585-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/12962348/pubmed\" target=\"_blank\" id=\"12962348\">12962348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guerrant RL, Van Gilder T, Steiner TS, et al, &quot;Practice Guidelines for the Management of Infectious Diarrhea,&quot; <i>Clin Infect Dis</i>, 2001, 32(3):331-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11170940/pubmed\" target=\"_blank\" id=\"11170940\">11170940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-D&iacute;az S and Mitchell AA, Author reply, <i>NEJM</i>, 2001, 344(12): 934-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, et al, &quot;Folic Acid Antagonists During Pregnancy and the Risk of Birth Defects,&quot; <i>N Engl J Med</i>, 2000, 343(22):1608-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/11096168/pubmed\" target=\"_blank\" id=\"11096168\">11096168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections (OIs) in HIV-Exposed and HIV-Infected Children. December 2016. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2017. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoppu K, &quot;Age Differences in Trimethoprim Pharmacokinetics: Need for Revised Dosing in Children?&quot; <i>Clin Pharmacol Ther</i>, 1987, 41(3):336-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/3816021/pubmed\" target=\"_blank\" id=\"3816021\">3816021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoppu K, &quot;Changes in Trimethoprim Pharmacokinetics After the Newborn Period,&quot; <i>Arch Dis Child</i>, 1989, 64(3):343-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2705795/pubmed\" target=\"_blank\" id=\"2705795\">2705795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jarosinki PF, Kennedy PE, and Gallelli JF, &ldquo;Stability of Concentrated Trimethoprim-Sulfamethoxazole Admixtures,&rdquo; <i>AJHP</i>, 1989, 46(4):732-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/2785757/pubmed\" target=\"_blank\" id=\"2785757\">2785757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee M, Bozzo P, Einarson A, et al, &quot;Urinary Tract Infections in Pregnancy,&quot; <i>Can Fam Physician</i>, 2008, 54(6):853-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/18556490/pubmed\" target=\"_blank\" id=\"18556490\">18556490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li PK, Szeto CC, Piraino B, et al, &quot;Peritoneal Dialysis-Related Infections Recommendations: 2010 Update,&quot; <i>Perit Dial Int</i>, 2010, 30(4):393-423<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20628102/pubmed\" target=\"_blank\" id=\"20628102\">20628102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrow SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children,&rdquo; <i>Clin Infect Dis</i>, 2011,52:1-38.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long S, Pickering L, eds. <i>Principles and Practice of Pediatric Infectious Diseases</i>. 4th ed. Philadelphia, PA: Saunders Elsevier; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Gorodischer R, Koren G, et al, &quot;Exposure to Folic Acid Antagonists During the First Trimester of Pregnancy and the Risk of Major Malformations,&quot;<i> Br J Clin Pharmacol</i>, 2009, 68(6):956-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/20002091/pubmed\" target=\"_blank\" id=\"20002091\">20002091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mattoo TK, &quot;Medical Management of Vesicoureteral Reflux - Quiz Within the Article. Don't Overlook Placebos,&quot; <i>Pediatr Nephrol</i>, 2007, 22(8):1113-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/17483966/pubmed\" target=\"_blank\" id=\"17483966\">17483966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, Salter AJ. The passage of trimethoprim/sulfamethoxazole into breast milk and its significance. Proceedings of the 8th international congress of chemotherapy, Athens. Hellenic Soc Chemother 1974;1:687-691.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitrano JA, Spooner LM, Belliveau P. Excretion of antimicrobials used to treat methicillin-resistant <i>Staphylococcus aureus</i> infections during lactation: safety in breastfeeding infants. <i>Pharmacotherapy</i>. 2009;29(9):1103-1109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19698015/pubmed\" target=\"_blank\" id=\"19698015\">19698015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. <i>Drug Saf</i>. 2000;22(3):227-236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/10738846/pubmed\" target=\"_blank\" id=\"10738846\">10738846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Springer C, Eyal F, and Michel J, &quot;Pharmacology of Trimethoprim-Sulfamethoxazole in Newborn Infants,&quot; <i>J Pediatr</i>, 1982, 100(4):647-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/7062219/pubmed\" target=\"_blank\" id=\"7062219\">7062219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al, &quot;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&quot; <i>Clin Infect Dis</i>, 2005, 41(10):1373-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/16231249/pubmed\" target=\"_blank\" id=\"16231249\">16231249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sulfamethoxazole and Trimethoprim tablet [prescribing information]. Pulaski, TN: AvKARE, Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients. <i>Paediatr Drugs</i>. 2004;6(1):45-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/14969569/pubmed\" target=\"_blank\" id=\"14969569\">14969569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32 Suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae Type 1,&quot; 2005. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ylikorkala O, Sj&ouml;stedt E, J&auml;rvinen PA, et al, &quot;Trimethoprim-Sulfonamide Combination Administered Orally and Intravaginally in the First Trimester of Pregnancy: Its Absorption Into Serum and Transfer to Amniotic Fluid,&quot; <i>Acta Obstet Gynecol Scand</i>, 1973, 52(3):229-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/4743777/pubmed\" target=\"_blank\" id=\"4743777\">4743777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12816 Version 211.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F154885\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F154886\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046614\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046607\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154857\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F154842\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F45703744\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046618\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F154877\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046617\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F154917\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154912\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154864\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154846\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25956058\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F154902\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154851\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154854\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F154867\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046613\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154845\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F154863\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F154866\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F154870\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12816|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information</a></li><li><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-patient-drug-information\" class=\"drug drug_patient\">Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information</a></li></ul></div></div>","javascript":null}